Home >> Tag Archives: Chembio Diagnostics—

Tag Archives: Chembio Diagnostics—

Chembio to sell its Sure Check HIV 1/2 Assay, 3/16

March 2016—Chembio Diagnostics will begin selling its Sure Check HIV 1/2 Assay in the U.S. market on June 1. The product is currently distributed in the United States by Alere under Alere’s Clearview Complete brand, and Chembio has notified Alere that it will not renew or extend the distribution agreement when it terminates on May 31.

Read More »

Chembio ends Alere distribution agreement

Feb. 10, 2016—Chembio Diagnostics will begin selling its Sure Check HIV 1/2 Assay in the U.S. market on June 1, 2016. The product is currently distributed in the U.S. by Alere under Alere’s Clearview Complete brand, and Chembio has notified Alere that it will not renew or extend the distribution agreement when it terminates May 31, 2016. The Sure Check ...

Read More »

Chembio agreement with CDC contractor, 2/15

February 2014—Chembio Diagnostics has entered a follow-on, milestone-based development agreement with a private contracting organization acting on behalf of the Centers for Disease Control and Prevention for a multiplex POC influenza immunity test using Chembio’s patented Dual Path Platform technology.

Read More »

Partnerships to develop POC diagnostic tests

January 2015—Chembio Diagnostics announced it has entered into an exclusive agreement with Integrated BioTherapeutics, a biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases. Under the terms of the agreement, Chembio will combine its patented Dual Path Platform technology with IBT’s proprietary Ebola reagents to develop POC diagnostic tests for Ebola and febrile illness. Chembio will have exclusive rights to any POC product developed through this agreement.

Read More »

HIV-syphilis assay, 1/14

January 2014—Chembio Diagnostics received its first purchase order for its DPP HIV-Syphilis Assay from its distributor in Mexico. The DPP HIV-Syphilis Assay is based on the company’s patented Dual Path Platform (DPP), a point-of-care testing platform that is suited to multiplexing and that adds a syphilis biomarker to the company’s FDA-approved DPP HIV 1/2 test. The addition of this marker has resulted in a fingerstick whole blood test that can help reduce the transmission of HIV and syphilis from mother to child.

Read More »

CE Mark for HIV 1/2 assay, 8/13:89

Chembio Diagnostics’ Sure Check HIV 1/2 assay has received CE Mark approval. The assay is now cleared for commercialization within the EU for rapid point-of-care detection of HIV. The product is FDA approved and distributed in the United States as Clearview Complete HIV 1/2 by Alere.

Read More »
X